Cidara Therapeutics Inc (CDTX) — Cash Flow-to-Debt Ratio
Cidara Therapeutics Inc (CDTX) has a Cash Flow-to-Debt Ratio of -0.42x as of September 2025, meaning its operating cash flow of $-40.62 Million could theoretically repay 0% of its total liabilities ($96.26 Million) in one year. Explore Cidara Therapeutics Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cidara Therapeutics Inc Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Cidara Therapeutics Inc across 12 annual periods. Also explore CDTX total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Cidara Therapeutics Inc (2013–2024)
Year-by-year debt coverage analysis for Cidara Therapeutics Inc. For market capitalisation and broader financial context, see Cidara Therapeutics Inc (CDTX) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.43x | $-176.53 Million | $51.49 Million | ▼ -1050.0% |
| 2023 | -0.30x | $-22.43 Million | $75.24 Million | ▲ +35.2% |
| 2022 | -0.46x | $-28.47 Million | $61.92 Million | ▲ +2.0% |
| 2021 | -0.47x | $-25.23 Million | $53.75 Million | ▲ +57.1% |
| 2020 | -1.09x | $-54.41 Million | $49.71 Million | ▼ -19.5% |
| 2019 | -0.92x | $-28.53 Million | $31.14 Million | ▲ +67.7% |
| 2018 | -2.84x | $-56.70 Million | $19.97 Million | ▼ -9.7% |
| 2017 | -2.59x | $-49.91 Million | $19.29 Million | ▼ -22.2% |
| 2016 | -2.12x | $-39.77 Million | $18.78 Million | ▲ +50.6% |
| 2015 | -4.28x | $-25.96 Million | $6.06 Million | ▼ -80.3% |
| 2014 | -2.37x | $-7.71 Million | $3.25 Million | ▼ -262.3% |
| 2013 | -0.66x | $-1.05 Million | $1.60 Million | — |